BIO-TECHNE Corp

For the period ended Dec 31, 2025. Filed Feb 4, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2025 · Filed Feb 4, 2026

TECH$72.82-0.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity


· · · · · · · · · · · · · Accumulated · · ·
· · · · · · · Additional · · · · · Other · · ·
· · Common Stock · · Paid-in · · Retained · · Comprehensive · ·
Six months ended December 31, 2025 · · Shares · · Amount · · Capital · · Earnings · · Loss · · Total
Balances at June 30, 2025	154,972	$1,550	$911,089	$1,066,049	$(59,880)	$1,918,808
Net earnings				38,185		38,185
Other comprehensive income					(4,515)	(4,515)
Share repurchases	(1)	0		(24)		(24)
Common stock issued for exercise of options	625	6	21,477	(5,895)		15,588
Common stock issued for restricted stock awards	110	1	(1)	(3,337)		(3,337)
Cash dividends ($0.08 per share)				(12,444)		(12,444)
Stock-based compensation expense			11,543			11,543
Common stock issued to employee stock purchase plan	43	0	2,012			2,012
Employee stock purchase plan expense			(2)			(2)
Balances at September 30, 2025	155,749	$1,557	$946,118	$1,082,534	$(64,395)	$1,965,814
Net earnings				38,009		38,009
Other comprehensive income					2,051	2,051
Common stock issued for exercise of options	100	1	4,738	—		4,739
Common stock issued for restricted stock awards	32	1	(1)	(1,254)		(1,254)
Cash dividends ($0.08 per share)				(12,470)		(12,470)
Stock-based compensation expense			13,727			13,727
Employee stock purchase plan expense			373			373
Balances at December 31, 2025	155,881	$1,559	$964,955	$1,106,819	$(62,344)	$2,010,989

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (Continued)


· · · · · · · · · · · · · Accumulated · · ·
· · · · · · · Additional · · · · · Other · · ·
· · Common Stock · · Paid-in · · Retained · · Comprehensive · ·
Six months ended December 31, 2024 · · Shares · · Amount · · Capital · · Earnings · · Loss · · Total
Balances at June 30, 2024	158,216	$1,582	$820,337	$1,325,247	$(78,316)	$2,068,850
Net earnings				33,600		33,600
Other comprehensive income					18,229	18,229
Common stock issued for exercise of options	577	6	23,224	(2,338)		20,892
Common stock issued for restricted stock awards	50	1	1	(2,646)		(2,644)
Cash dividends ($0.08 per share)				(12,688)		(12,688)
Stock-based compensation expense			10,146			10,146
Common stock issued to employee stock purchase plan	35	0	2,227			2,227
Employee stock purchase plan expense			38			38
Balances at September 30, 2024	158,878	$1,589	$855,973	$1,341,175	$(60,087)	$2,138,650
Net earnings				34,890		34,890
Other comprehensive income					(25,563)	(25,563)
Share repurchases	(1,118)	(11)		(75,617)		(75,628)
Common stock issued for exercise of options	132	1	5,183	(20)		5,164
Common stock issued for restricted stock awards	24	0	0	(993)		(993)
Cash dividends ($0.08 per share)				(12,736)		(12,736)
Stock-based compensation expense			14,335			14,335
Employee stock purchase plan expense			373			373
Balances at December 31, 2024	157,916	$1,579	$875,864	$1,286,699	$(85,650)	$2,078,492

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.